Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 17

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 17
---
 Sheets was $0.0990 per share. The Board also believes that a higher stock price may help generate investor interest in the Company. If the Reverse Stock Split successfully increases the per share price of our Common Stock, the Board of Directors also believes this increase may increase trading volume in our Common Stock and facilitate future financings by the Company. 7 As a result of our prior reverse stock splits, we are not entitled to a cure period for our failure to comply with the Bid Price Requirement within one year after our most recent reverse stock split. Failure to approve the Reverse Stock Split may have serious, adverse effects on the Company and its stockholders. Our shares are quoted on the OTC Bulletin Board or other small trading markets, which are generally considered to have less volume and be less efficient markets. We believe an investor likely would find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our Common Stock on an over -the-countermarket. Many investors likely would not buy or sell our Common Stock due to difficulty in accessing over -the-countermarkets, policies preventing them from trading in securities not listed on a national exchange, or other reasons. In that event, the Common Stock could trade thinly as a microcap or penny stock, adversely decrease to nominal levels of trading and may be avoided by retail and institutional investors, resulting in the impaired liquidity of our Common Stock. As of the Record Date, our Common Stock closed at $0.089 per share on the OTC Pink Sheets. The Reverse Stock Split, if effected, should have the immediate effect of increasing the price of our Common Stock, therefore potentially allowing us satisfy the Bid Price Requirement and regain listing on Nasdaq. However, the price of our Common Stock has declined after each prior reverse stock split and we cannot assure you that the price of our Common Stock will not decline after the Reverse Stock Split as well. Our Board strongly believes that the Reverse Stock Split is necessary to regain listing on Nasdaq and to thereby provide us with a market for our Common Stock that is more accessible than our current market, OTC Pink Sheets. Accordingly, the Board recommended that our shareholders approve the Reverse Stock Split Proposal to effect the Reverse Stock Split and directed that this proposal be submitted to our shareholders for approval at the Special Meeting, including for the reasons discussed below. Appeal to a Broader Range of Investors to Generate Greater Investor Interest in the Company An increase in our stock price may make our Common Stock more attractive to investors. Brokerage firms may be reluctant to recommend lower -priced